Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial)
Publication date: August 2026 Source: Journal of the National Cancer Center, Volume 6, Issue 4 Author(s): Yi Miao, Ming Liu, Shuchao Qin, Fei Li, Jin Zhang, Hongling Peng, Chunyan Ji, Luomengjia Dai, Ziyuan Zhou, Chongyang Ding, Zhen Wang, Yeqin Sha, Tonglu Qiu, Hanning Tang, Hui Jin, Lei Fan, Wei Xu, Jianyong Li, Yi Xia, Huayuan Zhu
Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial). // Journal of the National Cancer Center. – URL: https://www.sciencedirect.com/science/article/pii/S2667005426000554?dgcid=rss_sd_all
Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial). Journal of the National Cancer Center. https://www.sciencedirect.com/science/article/pii/S2667005426000554?dgcid=rss_sd_all
“Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).” Journal of the National Cancer Center.
@article{article55765,
title = {Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial)},
journal = {Journal of the National Cancer Center},
url = {https://www.sciencedirect.com/science/article/pii/S2667005426000554?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment